We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Gene Bridges Granted Korean Patent for Recombineering Technology

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gene Bridges Granted Korean Patent for Recombineering Technology"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Gene Bridges GmbH, the recombineering company, announced that it has been granted Korean Patent No. 10-0751587, entitled "Methods and compositions for directed cloning and sub-cloning using homologous recombination" by the Korean Patent Office.

The patent broadly covers the major areas of Gene Bridges’ RED/ET recombineering technology. This is the same technology that is already covered by issued patents in the USA and EU.

Gary Stevens, CEO of Gene Bridges GmbH, commented: ‘Recombineering is the technology of choice in DNA engineering and is used worldwide in industry and academia. In addition to the patents already granted Gene Bridges, this forms a part of the strong intellectual property position Gene Bridges is building worldwide. Korea has an important and growing life sciences sector and we look forward to working with the leading institutes and companies there.’

Red/ET is a revolutionary method for DNA engineering. Recombineering with Red/ET allows unlimited cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including very large ones such as BACs or the E.coli chromosome.